Notícias

Novo Nordisk (NVO) said Thursday that China's National Medical Products Administration has accepted

Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.

Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment

A simpler diagnostic tool could widen Alzheimer's testing access

Healthcare stocks fell late Wednesday afternoon, with the NYSE Healthcare Index shedding 1% and the

The drugmaker's stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.

While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That drug now represents a small fraction of the Innovative Medicine portfolio. The remaining 96% of that business is posting remarkable growth, expanding at over 14.

The payer argument looks powerful, but the study measures medical savings before charging for the medicine.

Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,’ has been granted approval in patients with pancreatic adenocarcinoma.

Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment.

The past year's gain was bought with volume and access, and management has already said net price goes lower from here.

Researchers used two analytical methods, both of which showed that monthly healthcare costs fell over time, but neither included the cost of Zepbound.

Eli Lilly (NYSE:LLY) agreed a new research and collaboration deal with BioArctic that applies BioArctic's BrainTransporter technology to a potential Alzheimer's treatment. The BioArctic agreement expands Eli Lilly's drug development activity in neurodegenerative disease beyond its existing diabetes and obesity portfolio. New real-world data report that adults over 55 with obesity who stay on Zepbound for longer periods record lower healthcare costs than those who do not. The Zepbound...

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

Europe gives Lilly another market for its oral obesity franchise, but reimbursement will determine the launch's financial weight.

Its growth profile stands well above major sector peers.

Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science

Beyond strong drugs, the stock’s ascent was powered by its notable profitability.

Dow Jones AI giant Nvidia stock is trying to find support at a key level. Nvidia earnings are due Wednesday after the close.

Blue chip stocks dominate the list of hedge funds' most popular equity investments.

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.

Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.

Eli Lilly and Novo Nordisk both dominated GLP-1 headlines in Q2 2026, but one company raised guidance while the other announced layoffs, pipeline writedowns, and a dramatic price cut. The split screen tells a story that goes beyond which drug sells more.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Management is betting on a bigger year than ever, but investors seem to be waiting for a catch.

Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre

The obesity-drug leader is retreating despite growth that remains extraordinary by mega-cap standards.

On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide. It is an experimental obesity drug still in Phase 3 trials and not yet approved by regulators anywhere. Why This Matters Lilly is trying to shut down a […]